These results demonstrate that TransCon PTH therapy has the potential to provide significant and sustained improvements not only in clinical outcomes but also in HRQoL and symptoms in adults with hypoparathyroidism, which were observed as early as 10 weeks after initiation of treatment in the PaTHway trial. This evidence concerns the gene PTH and hypoparathyroidism.